Blood Epidemiology and Clinical Therapeutics

Funding for benign blood diseases and cell therapies (e.g., hematopoietic stem cell transplants, transfusion products, and novel cell therapies), including development and dissemination of data science resources in patient-reported outcomes.

Program Officers

Nahed El Kassar, M.D., Ph.D.
Hematologic clinical trials; Women’s health; HSCT late effects
301-435-0065
Shimian Zou, Ph.D.
NHLBI HIV/AIDS Coordinator; Epidemiology; Transfusion
301-435-0065
Benyam Hailu, MD, MPH
Clinical studies; Transfusion; health disparities
301-435-0065
William P. Tonkins, Dr. PH, J.D.
Behavioral science; Sickle cell disease; Pain; PROs
301-435-0065